Temporomandibular Arthritis in a Patient with Psoriasis vulgaris under Systemic Etretinate Therapy
Toshiyuki Yamamoto,Kyoko Watanabe,K. Nishioka
DOI: https://doi.org/10.1159/000078597
2004-07-01
Dermatology
Abstract:Joint involvement affecting temporomandibular joints is very rare in patients with psoriasis. Rasmussen and Bakke [1] showed several characteristics of temporomandibular arthritis as follows: (1) there is no sex predilection; (2) unilateral involvement is most common; (3) erosive changes are seen more frequently than proliferative changes; (4) pain, swelling and limitation of movement are common clinical features, and (5) age at onset of symptoms is variable, usually beginning in the second decade of life or later. Systemic retinoid therapy has been proved to be effective for severe psoriasis, including pustular psoriasis and erythrodermic psoriasis [2, 3]. Systemic side effects can occur in retinoid-treated patients. The spectrum of musculoskeletal adverse effects shows spur formation, ossification and calcification of ligaments, cortical hyperostosis and periosteal thickening with multiple skeletal sites [4–7]. We herein report a case of temporomandibular arthritis in a patient with psoriasis vulgaris under oral etretinate therapy. A 52-year-old female had been suffering from psoriasis vulgaris for several years. She developed typical psoriatic lesions on the scalp, trunk and extremities. Histological examination showed acanthosis, hyperkeratosis with parakeratosis, long edematous papillae and round-cell infiltrates in the upper dermis. The PASI score was 17.0. She did not complain of joint pain, and she was seronegative for rheumatoid factor. HLA typing revealed A24, A31, B39, B54, Cw1 and Cw7 specificities. She had been treated with topical steroids, anthralin and vitamin D3, with unfavorable results. Oral etretinate (Tigason®) was initiated at a dose of 30 mg daily, which showed an effect. Thereafter, she had been treated with etretinate with a dose of 20–30 mg daily. Ten months later, she noted pain at the right temporomandibular joint, which was exacerbated by talking and eating. She denied joint pain of other sites, and physical examination did not reveal any joint swelling of the fingers or toes. Bone scintigraphy by 99mTc-HMDP showed increased fixation on the right temporomandibular junction (fig. 1). After the stoppage of the etretinate therapy, her jaw pain rapidly improved and disappeared within 3 months. The total dose of etretinate was 8,960 mg. Although an increased incidence of temporomandibular joint pain and limitation of motion has been reported in patients with psoriasis arthropathy, as compared with control groups [8], temporomandibular joint dysfunction is rarely seen in psoriasis arthropathy [9]. In particular, psoriasis arthropathy affecting the temporomandibular joints is seen in patients with HLA-B27, appearing as localized jaw pain, swelling and limitation of movement. In the present case, she developed temporomandibular arthritis during oral etretinate Fig. 1. Results of bone scan by 99mTc-HMDP, showing a prominently increased fixation in the right temporomandibular junction.